In May 2019, Bank of New York Mellon became a substantial holder with 27.09%
Since then there have been Research reports, New Stories, Media Stories and Company announcements and Presentations ETC
And P Hopper the main man behind GDC0084 from Giloblast who originally licenced the drug from Genentech decided to sell most of his entire holding at 33.08c
P Hopper has the capital to take this over or fund it in its entirety with his $500m recent sale
Many claim this has been an artificial fall and the price should be back to mid 40's- DYOR
IMO
With all the media coverage and above lately this should be well above mid 40's but unfortunately
Cantrixil and GDC0084 need partners or significant funds and the market is fully aware of the past and how shareholders have been burnt to the tune of 90% from the last big CR
DYOR imo be cautious until funding details for forward planning are released
